Aripiprazole Pharmacotherapy of Borderline Personality Disorder

We report three consecutive cases of women with borderline personality disorder with psychotic symptoms, who received pharmacotherapy with the new atypical antipsychotic drug aripiprazole. Therapeutic effects were measured using the SCL-90R (symptom check list) and the BSL (borderline symptom list). We observed different responses to aripiprazole. In the first patient we had to discontinue the drug before we were able to observe any therapeutic effects. The second patient also complained about initial side effects. However, after the dose was lowered, the drug was tolerated and she responded well to aripiprazole with respect to all psychopathological aspects. The third patient did not suffer from any side effects under aripiprazole. She responded partially to the drug. Aripiprazole may have a potential role in the pharmacotherapy of borderline personality disorder and may not only target psychotic symptoms in these patients.

References

• 1 American Psychiatric A ssociation. Practice guidelines for the treatment of patients with borderline personality disorder.  Am J Psychiatry. 2001;  158 1-52
• 2 Bohus M, Limberger M F, Frank U, Sender I, Gratwohl T, Stieglitz R D. Development of the borderline symptom list.  Psychother Psychosom Med Psychol. 2001;  51 201-211
• 3 Bohus M, Frank U, Limberger M F, Zanarini M, Chapman A, Stieglitz R D. Psychometric Properties of the Borderline Symptom List (BSL). Psychpathology; in press
• 4 Derogatis L R, Lipman R S, Covi L. SCL-90: An outpatient psychiatric rating scale - preliminary report.  Psychopharmacology Bulletin. 1973;  9 13-28
• 5 Grootens KP and Verkes R J. Emerging evidence for the use of atypical antipsychotics in borderline personality disorder.  Pharmacopsychiatry. 2005;  38 20-23
• 6 Linehan M M, Armstrong H E, Suarez A, Allmon D, Heard H L. Cognitive-behavioral treatment of chronically parasuicidal borderline patients.  Arch Gen Psychiatry. 1991;  48 060-1064
• 7 Soler J, Pasqual J C, Campins J, Barrachina J, Puigdemont D, Alvarez E, Perez V. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder.  Am J Psychiatry. 2005;  162 221-1224
• 8 Zanarini MC and Frankenburg F R. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study.  J Clin Psychiatry. 2001;  62 849-854
• 9 Zanarini M C, Frankenburg F R, Parachini E A. A preliminary, randomized trial of fluoxetine, olanzapine and the olanzapine-fluoxetine combination in women with borderline personality disorder.  J Clin Psychiatry. 2004;  65 903-907